To evaluate whether combining GFAP and NfL could increase their specificity in diagnosing AE, we compared CSF and serum NfL/GFAP ratios between active AE patients and age‐matched active progressive MS patients, age‐matched inactive MS patients, and controls. Here, GFAP is linked to myeloid sarcoma.